Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial — Yutao Guo (2020) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial
Shared by
Professor Gregory Lip
University of Liverpool
Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial
Article
2020
en
Authors
+1 more
YG
Yutao Guo
DL
Deirdre A. Lane
YC
Yundai Chen
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2020
Regular reassessment of bleeding risk using the HAS-BLED score reduces bleeding outcomes in a prospective cohort: a report from the mAFA II clinical trial extension
Yanxing Guo
,
Deirdre A. Lane
,
Y Chen
,
Professor Gregory Lip
Article
2022
Mobile health-technology integrated care in atrial fibrillation patients with heart failure: A report from the mAFA-II randomized clinical trial
Yutao Guo
,
Giulio Francesco Romiti
,
Bernadette Corica
,
Marco Proietti
,
Niccolò Bonini
,
Hui Zhang
,
Professor Gregory Lip
Article
2021
Improving outcomes with integrated care of patients with atrial fibrillation and multimorbidity using mobile health technology: a report from the mAFA II trial
Yutao Guo
,
Professor Gregory Lip
Article
2023
Mobile Health-Technology-Integrated Care for Atrial Fibrillation: A Win Ratio Analysis from the mAFA-II Randomized Clinical Trial
Giulio Francesco Romiti
,
Yutao Guo
,
Bernadette Corica
,
Marco Proietti
,
Hui Zhang
,
Professor Gregory Lip
Article
2023
Mobile health technology integrated care in atrial fibrillation patients with diabetes mellitus in China: A subgroup analysis of the mAFA‐II cluster randomized clinical trial
Yutao Guo
,
Bernadette Corica
,
Giulio Francesco Romiti
,
Marco Proietti
,
Hui Zhang
,
Professor Gregory Lip
Discussion(0)
No comments yet. Be the first to comment.